Gain Therapeutics to Present Positive Preclinical Data on its GBA1 Program at the AD/PD 2023 Meeting

Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer’s diseaseBETHESDA, Md., March 29, 2023 -- Gain... | March 29, 2023

Related Keywords

Sweden ,Gothenburg ,Vastra Gotalands Lan ,Joanne Taylor ,Matthias Alder ,Exchange Commission ,Nasdaq ,Company Annual Report On Form ,Gain Therapeutics Inc ,Michaelj Fox Foundation For Parkinson Research ,Exchange Commission On ,Silverstein Foundation For Parkinson ,Head Of Research ,International Conference On Alzheimer ,Science Technology ,European Union Horizon ,Chief Executive ,Amyloid Beta ,Cell Based Models ,Gain Therapeutics ,Silverstein Foundation ,Private Securities Litigation Reform Act ,Annual Report ,Media Contact ,Nc Stock Exchange ,News ,Information ,Press Release ,Study ,Results ,Support ,The ,Potential ,F ,Structurally ,Argeted ,Llosteric ,Regulators ,Case ,Or ,Treatment ,Arch ,023 Ganx Us36269b1052 ,